Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.86 |
| ▸ | BID | P55957 | 1/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.86 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.86 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.86 |
| ▸ | ASPH | Q12797 | 1/20 | 0.86 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.86 |
| ▸ | BAD | Q92934 | 1/20 | 0.86 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.86 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702539 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1957486 | 0.96 | BCL2 (0.93) | BCL2 | |
| SCHEMBL1955090 | 0.96 | BCL2 (0.92) | BCL2 | |
| SCHEMBL19419621 | 0.96 | BCL2 (0.92) | BCL2 | |
| SCHEMBL19911640 | 0.96 | BCL2 (0.92) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL2483608 | 0.96 | BCL2 (0.92) | BCL2 | |
| SCHEMBL1957657 | 0.96 | BCL2 (0.92) | BCL2 | |
| SCHEMBL1954728 | 0.96 | BCL2 (0.92) | BCL2 | |
| SCHEMBL1958638 | 0.96 | BCL2 (0.92) | BCL2 | |
| SCHEMBL1702665 | 0.95 | BCL2 (1.00) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | disclosed |